IDO Targeting in Sarcoma: Biological and Clinical Implications

Sarcomas are heterogeneous malignant mesenchymal neoplasms with limited sensitivity to immunotherapy. We recently demonstrated an increase in Kynurenine Pathway (KP) activity in the plasma of sarcoma patients treated with pembrolizumab. While the KP has already been described to favor immune escape...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Immunol
Main Authors: Nafia, Imane, Toulmonde, Maud, Bortolotto, Doriane, Chaibi, Assia, Bodet, Dominique, Rey, Christophe, Velasco, Valerie, Larmonier, Claire B., Cerf, Loïc, Adam, Julien, Le Loarer, François, Savina, Ariel, Bessede, Alban, Italiano, Antoine
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2020
Assuntos:
Immunology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7066301/
https://ncbi.nlm.nih.gov/pubmed/32194552
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.00274
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados